Technology evaluation: mapatumumab, Human Genome Sciences/GlaxoSmithKline/Takeda
Vulfovich, M.; Saba, N.
Current Opinion in Molecular Therapeutics 7(5): 502-510
2005
ISSN/ISBN: 1464-8431 PMID: 16248286 Document Number: 592662
Human Genome Sciences and GlaxoSmithKline, under license from Cambridge Antibody Technology, are developing mapatumumab, the intravenously administered lead from a series of human monoclonal antibody tumor necrosis factor-related apoptosis-inducing ligand receptor 1 agonists, for the potential treatment of cancer. The therapy is currently undergoing phase II clinical trials. Takeda is developing mapatumumab in Japan.
Document emailed within 1 workday
Related Documents
Golab, J.; Stoklosa, T. 2005: Technology evaluation: SB-485232, GlaxoSmithKline Current Opinion in Molecular Therapeutics 7(1): 85-93Gnanakumaran, G.; Babu, K.S. 2003: Technology evaluation: mepolizumab, GlaxoSmithKline Current Opinion in Molecular Therapeutics 5(3): 321-325
Gevers, W. 2003: The social sciences, the human genome and human nature South African Medical Journal 93(5): 354-356
Sun, S. 2000: Technology evaluation: SELEX, Gilead Sciences Inc Current Opinion in Molecular Therapeutics 2(1): 100-105
Mangiapane, M.; Foong, P. 2022: How Australia's Policymakers can Ethically Approach Human Germline Genome Editing Technology Journal of Law and Medicine 29(3): 740-759
Georgiev, G.P. 1977: Study of the structure of the genome of eukaryotes at the Institute of Molecular Biology of the Academy of Sciences of the USSR Molekuliarnaia Biologiia 11(6): 1274-1282
Tobies, R. 2008: Mathematik, Naturwissenschaften und Technik als Bestandteile der Kultur der Gegenwart - Mathematics, Natural Sciences and Technology : Parts of the Encyclopedia Die Kultur der Gegenwart (The culture of today) - Les mathématiques, les sciences naturelles et la technologie : parties de l'encyclopédie Die Kultur der Gegenwart (La culture du présent) Gemeinsame Jahrestagung der Gesellschaft für Wissenchaftsgeschichte und der Deutschen Gesellschaft für Geschichte der Medizin, Naturwissenschaften und Technik (Braunschweig 2006-09) 31(1): 29-43
Charland, P.; Potvin, P. 2009: Santé, énergie et environnement: une intégration de l'éducation relative à l'environnement au curriculum de sciences et technologie du secondaire (lycée) - Health, energy and environment : an integration of environmental education in curriculum of sciences and technology in secondary education (high school) Liaison Energie Francophonie (82): 30-34
Kamarád, J.; Cepelková, M. 1998: High pressure technology and examples of its use in the biological sciences Sbornik Lekarsky 99(4): 529-538
Marwick, C. 1989: Technology, cost, cooperation, ethics challenges face genome mapping plan JAMA 262(23): 3247
Abelmann, W.H.; Nave, B.D.; Wilkerson, L. 1997: Generation of physician-scientists manpower: a follow-up study of the first 294 graduates of the Harvard-MIT Program of Health Sciences and Technology Journal of Investigative Medicine: the Official Publication of the American Federation for Clinical Research 45(5): 272-275
Mikhaĭlitsyn, F.S.; Petrov, I.F.; Bol'shakova, A.I.; Lebedeva, M.N.; Lychko, N.D. 1995: The technology for manufacturing antiparasitic preparations. 4. the development of a technology for producing the anthelmintic bromoksan in finely dispersed form and the evaluation of its antifascioliasis activity Meditsinskaia Parazitologiia i Parazitarnye Bolezni 3: 41-42
Jonas, M.; Malpas, P.; Kersey, K.; Merry, A.; Bagg, W. 2017: Applying ethical and legal principles to new technology: the University of Auckland Faculty of Medical and Health Sciences' policy 'Taking and Sharing Images of Patients.' New Zealand medical journal 130(1449): 30-38
Beach, S.R.; Schulz, R.; Matthews, J.T.; Courtney, K.; Dabbs, A.DeVito. 2014: Preferences for technology versus human assistance and control over technology in the performance of kitchen and personal care tasks in baby boomers and older adults Disability and Rehabilitation. Assistive Technology 9(6): 474-486
Mikhaĭlitsyn, F.S.; Drusviatskaia, S.K.; Uvarova, N.A.; Taits, S.Z.; Stoianovich, F.M.; Vol'kenshteĭn, I.B.; Lebedeva, M.N.; Krotov, A.I.; Lychko, N.D. 1994: The technology for manufacturing antiparasitic preparations. 3. the development of a technology for producing the anthelmintic embovin (pyrantel embonate) in finely dispersed form and the evaluation of its anthelmintic properties Meditsinskaia Parazitologiia i Parazitarnye Bolezni 2: 24-26
Arvin, A.M. 2002: Varlirix (GlaxoSmithKline) Current Opinion in Investigational Drugs 3(7): 996-999
Cheson, B. 2002: Bexxar (Corixa/GlaxoSmithKline) Current Opinion in Investigational Drugs 3(1): 165-170
Krupat, E.; Mesler, M.A. 1992: Social and behavioural sciences at the Massachusetts College of Pharmacy and Allied Health Sciences Journal of Clinical Pharmacy and Therapeutics 17(1): 3-5
Castro, R. 1996: Social sciences and health sciences: difficulties of interaction and solution alternatives Salud Publica de Mexico 38(4): 225-226
Suchodolski, B. 1974: Le Soleil du Monde ou la Signification de Copernic dans l'evolution des Sciences Naturelles et Sciences Humaines Organon (10): 61-74